OnCo

Financial help and assistance navigator

Where the money can come from. OnCo records access and cost information on 95 products: manufacturer assistance programmes, reimbursement decisions and whether a generic exists, country by country. This page gathers all of it in one place, adds the national schemes and charities that pay for care or living costs in each country, and the patient organisations that run copay and travel funds. Filter to your country and your treatments, then print the list.

161 rows · 41 with a manufacturer programme

Country follows the region switcher in the header; products are seeded from the treatments in your browser profile. Nothing leaves your device. Print gives a one-page list to take to a social worker or financial navigator.

Per-product help in all countries

From each product's access record; blank means not recorded, not that nothing exists.
ProductCountryManufacturer programmeReimbursementGeneric
Abemaciclib
Small-molecule CDK4/6 inhibitor
United KingdomNot recordedNICE: recommended with fulvestrant (TA579), aromatase inhibitor (TA563), and adjuvant (TA810)Not recorded
Abemaciclib
Small-molecule CDK4/6 inhibitor
United Stateslillycares.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Actinium-225 DOTATATE
Targeted alpha therapy
United StatesNot recordedInvestigationalNot recorded
Actinium-225 PSMA agents
Targeted alpha therapy
GermanyNot recordedCompassionate use at selected centres (Heidelberg and others)Not recorded
Actinium-225 PSMA agents
Targeted alpha therapy
United StatesNot recordedInvestigational (phase 3)Not recorded
Adagrasib
Small-molecule inhibitor (KRAS G12C)
United KingdomNot recordedNICE: appraisal for KRAS G12C NSCLC (2025)Not recorded
Adagrasib
Small-molecule inhibitor (KRAS G12C)
United Statesbmsaccesssupport.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Afamitresgene autoleucel
TCR-T (MAGE-A4)
United StatesNot recordedMedicare Part B (inpatient/outpatient); commercial per planNot recorded
AK146D1
Bispecific ADC
ChinaNot recordedInvestigationalNot recorded
Amivantamab
Bispecific antibody (EGFR×MET)
United KingdomNot recordedNICE: recommended with lazertinib for untreated EGFR-mutant NSCLC (2025) and exon 20 insertion after platinumNot recorded
Amivantamab
Bispecific antibody (EGFR×MET)
United Statesjanssencarepath.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
ArteraAI Breast
AI digital pathology risk test
United StatesNot recordedLaunched May 2026; coverage determinations pendingNot recorded
ArteraAI Prostate
AI digital pathology prognostic/predictive test
United StatesNot recordedMedicare coverage via MolDX; NCCN-listedNot recorded
Atezolizumab
Monoclonal antibody (anti-PD-L1)
United KingdomNot recordedNICE: recommended in NSCLC (several TAs), SCLC with chemotherapy, HCC with bevacizumab, adjuvant NSCLCNot recorded
Atezolizumab
Monoclonal antibody (anti-PD-L1)
United Statesgenentech-access.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Autogene cevumeran
Personalised mRNA neoantigen vaccine
United StatesNot recordedInvestigational (phase 2 IMCODE003)Not recorded
Axicabtagene ciloleucel
CAR-T (CD19)
United KingdomNot recordedNICE: recommended for relapsed/refractory DLBCL after ≥2 therapies (TA872) and second-line early relapse (TA895)Not recorded
Axicabtagene ciloleucel
CAR-T (CD19)
United Stateskitekonnect.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Belantamab mafodotin
ADC
United KingdomNot recordedNICE: recommended in combination regimens for relapsed myeloma (2025)Not recorded
Belantamab mafodotin
ADC
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Belzutifan
Small-molecule HIF-2α inhibitor
United KingdomNot recordedNICE: appraisal for RCC after IO and VEGF-TKI (2025-26)Not recorded
Belzutifan
Small-molecule HIF-2α inhibitor
United Statesmerckaccessprogram-welireg.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Blinatumomab
Bispecific T-cell engager (CD19×CD3)
United KingdomNot recordedNICE: recommended in Ph-negative relapsed/refractory B-ALL (TA450) and MRD-positive ALL (TA589)Not recorded
Blinatumomab
Bispecific T-cell engager (CD19×CD3)
United Statesamgensupportplus.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Brentuximab vedotin
ADC
United KingdomNot recordedNICE: recommended in CD30+ Hodgkin lymphoma settings (TA446, TA524) and first-line stage IV with AVDNot recorded
Brentuximab vedotin
ADC
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Capivasertib
Small-molecule AKT inhibitor
United KingdomNot recordedNICE: recommended with fulvestrant for PIK3CA/AKT1/PTEN-altered HR+ breast cancer (TA998)Not recorded
Capivasertib
Small-molecule AKT inhibitor
United Statesastrazeneca-us.com/medicines/access-360Medicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Carboplatin
Cytotoxic chemotherapy (platinum)
United KingdomNot recordedNHS standard; genericYes
Carboplatin
Cytotoxic chemotherapy (platinum)
United StatesNot recordedMedicare Part B; genericYes
Cemiplimab
Monoclonal antibody (anti-PD-1)
United KingdomNot recordedNICE: recommended for advanced cutaneous squamous cell carcinoma (TA592) and PD-L1 ≥50% NSCLCNot recorded
Cemiplimab
Monoclonal antibody (anti-PD-1)
United Stateslibtayosurroundcare.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Ciltacabtagene autoleucel
CAR-T (BCMA)
United KingdomNot recordedNICE: recommended for relapsed myeloma after ≥1 line, lenalidomide-refractory (2025)Not recorded
Ciltacabtagene autoleucel
CAR-T (BCMA)
United Statesjanssencarepath.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Daraxonrasib
Small-molecule pan-RAS(ON) inhibitor
United StatesNot recordedInvestigational; NDA expected after RASolute 302Not recorded
Datopotamab deruxtecan
ADC
United KingdomNot recordedNICE: appraisal in progress for HR+/HER2- breast cancer; not yet recommended (2026)Not recorded
Datopotamab deruxtecan
ADC
United Statesdatroway.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Disitamab vedotin
ADC
ChinaNot recordedNMPA approved 2021; on the National Reimbursement Drug ListNot recorded
Disitamab vedotin
ADC
United StatesNot recordedInvestigational (Pfizer; phase 3 in urothelial cancer)Not recorded
Dostarlimab
Monoclonal antibody (anti-PD-1)
United KingdomNot recordedNICE: recommended with chemotherapy for dMMR/MSI-H advanced endometrial cancer (TA1068)Not recorded
Dostarlimab
Monoclonal antibody (anti-PD-1)
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Doxorubicin
Cytotoxic chemotherapy (anthracycline)
United StatesNot recordedNot recordedYes
Durvalumab
Monoclonal antibody (anti-PD-L1)
United KingdomNot recordedNICE: recommended after chemoradiation in stage III NSCLC (TA798), biliary tract cancer, limited-stage SCLC, perioperative bladder and gastric cancerNot recorded
Durvalumab
Monoclonal antibody (anti-PD-L1)
United Statesastrazeneca-us.com/medicines/access-360Medicare Part B (physician-administered); commercial plans per formularyNot recorded
Elacestrant
Oral SERD
United KingdomNot recordedNICE: recommended for ESR1-mutated ER+/HER2- advanced breast cancer (2024)Not recorded
Elacestrant
Oral SERD
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Encorafenib
Small-molecule kinase inhibitor (BRAF)
United KingdomNot recordedNICE: recommended with binimetinib in BRAF V600 melanoma (TA562) and with cetuximab in BRAF V600E CRC (TA668)Not recorded
Encorafenib
Small-molecule kinase inhibitor (BRAF)
United Statespfizeroncologytogether.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Enfortumab vedotin
ADC
European UnionNot recordedEMA approved 2022 (monotherapy), 2024 (with pembrolizumab)Not recorded
Enfortumab vedotin
ADC
United KingdomNot recordedNICE: recommended with pembrolizumab for untreated advanced urothelial cancer (2024)Not recorded
Enfortumab vedotin
ADC
United Statespadcev.com/supportMedicare Part B (physician-administered); commercial plans per formularyNot recorded
FAP-2286 (177Lu / 68Ga)
Theranostic pair (peptide radioligand)
United StatesNot recordedInvestigationalNot recorded
FoundationOne CDx / Liquid CDx
Comprehensive genomic profiling test
United StatesNot recordedMedicare national coverage for FDA-approved CGP in advanced cancer (NCD 90.2); commercial coverage broadNot recorded
Galleri
Multi-cancer early detection blood test
United KingdomNot recordedNot available on the NHS; trial access via NHS-GalleriNot recorded
Galleri
Multi-cancer early detection blood test
United StatesNot recordedNot covered by Medicare (pending FDA decision and the MCED Screening Coverage Act); some employer and Medicare Advantage programmes coverNot recorded
Gedatolisib
Small-molecule pan-PI3K/mTOR inhibitor
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Gemtuzumab ozogamicin
ADC
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Glofitamab
Bispecific T-cell engager (CD20×CD3, 2:1)
United KingdomNot recordedNICE: recommended for relapsed/refractory DLBCL after ≥2 therapies (TA927)Not recorded
Glofitamab
Bispecific T-cell engager (CD20×CD3, 2:1)
United Statesgenentech-access.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Ifinatamab deruxtecan
ADC
United StatesNot recordedInvestigational (phase 3 IDeate-Lung02)Not recorded
Imatinib
Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)
United KingdomNot recordedNHS standard; genericYes
Imatinib
Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)
United StatesNot recordedMedicare Part D; generic since 2016 (list price fell >90%)Yes
Inavolisib
Small-molecule PI3Kα inhibitor and degrader
United KingdomNot recordedNICE: appraisal for PIK3CA-mutant HR+ breast cancer (2025-26)Not recorded
Inavolisib
Small-molecule PI3Kα inhibitor and degrader
United Statesgenentech-access.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Intismeran autogene
Personalised mRNA neoantigen vaccine
United StatesNot recordedInvestigational; BLA expected 2026-27 after INTerpath-001Not recorded
Ipilimumab
Monoclonal antibody (anti-CTLA-4)
United KingdomNot recordedNICE: recommended with nivolumab in melanoma, RCC, MSI-H CRC, mesothelioma, HCCNot recorded
Ipilimumab
Monoclonal antibody (anti-CTLA-4)
United Statesbmsaccesssupport.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Ivonescimab
Bispecific antibody (PD-1×VEGF)
ChinaNot recordedNMPA approved 2024; NRDL inclusion 2025Not recorded
Ivonescimab
Bispecific antibody (PD-1×VEGF)
United StatesNot recordedInvestigational; BLA under review (PDUFA 14 November 2026)Not recorded
Izalontamab brengitecan
Bispecific ADC
ChinaNot recordedNMPA filings under review (2026)Not recorded
Izalontamab brengitecan
Bispecific ADC
United StatesNot recordedInvestigational; BMS filing expected after BL-B01D1-307Not recorded
Lenalidomide
Immunomodulatory drug (cereblon E3 ligase modulator)
United StatesNot recordedNot recordedYes
Lifileucel
TIL cell therapy
European UnionNot recordedEMA approved 2025; national pricing pendingNot recorded
Lifileucel
TIL cell therapy
United Statesiovancecares.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Loncastuximab tesirine
ADC
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Lorlatinib
Small-molecule kinase inhibitor (ALK/ROS1)
United KingdomNot recordedNICE: recommended first-line for ALK+ NSCLC (TA909)Not recorded
Lorlatinib
Small-molecule kinase inhibitor (ALK/ROS1)
United Statespfizeroncologytogether.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Lutetium-177 dotatate
Radioligand therapy (beta)
United KingdomNot recordedNICE: recommended for unresectable/metastatic GEP-NETs (TA539)Not recorded
Lutetium-177 dotatate
Radioligand therapy (beta)
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Lutetium-177 vipivotide tetraxetan
Radioligand therapy (beta)
United KingdomNot recordedNICE: recommended for PSMA+ mCRPC after ARPI and taxane (2025); pre-chemotherapy appraisal in progressNot recorded
Lutetium-177 vipivotide tetraxetan
Radioligand therapy (beta)
United Statesnovartis.com/us-en/patient-supportMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Mirvetuximab soravtansine
ADC
United KingdomNot recordedNICE: recommended for FRα-high platinum-resistant ovarian cancer (2025)Not recorded
Mirvetuximab soravtansine
ADC
United Stateselahere.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Niraparib
Small-molecule PARP inhibitor
United KingdomNot recordedNICE: recommended for ovarian maintenance (TA528, TA673) and with abiraterone in BRCA-mutant prostate cancer (Akeega)Not recorded
Niraparib
Small-molecule PARP inhibitor
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Nivolumab
Monoclonal antibody (anti-PD-1)
United KingdomNot recordedNICE: recommended across melanoma, NSCLC, RCC, Hodgkin, HNSCC, gastric/oesophageal, urothelial, MSI-H CRC indicationsNot recorded
Nivolumab
Monoclonal antibody (anti-PD-1)
United Statesbmsaccesssupport.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Olaparib
Small-molecule PARP inhibitor
European UnionNot recordedEMA approved across indicationsNot recorded
Olaparib
Small-molecule PARP inhibitor
United KingdomNot recordedNICE: recommended in ovarian maintenance (TA598, TA620), adjuvant gBRCA breast (TA886), metastatic breast (TA1100), prostate (TA887)Not recorded
Olaparib
Small-molecule PARP inhibitor
United Statesastrazeneca-us.com/medicines/access-360Medicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Oncotype DX
Gene-expression prognostic/predictive assay
United KingdomNot recordedNICE: recommended for ER+/HER2- node-negative and some node-positive early breast cancer (DG58)Not recorded
Oncotype DX
Gene-expression prognostic/predictive assay
United StatesNot recordedMedicare and most commercial plans for node-negative and node-positive (1-3) HR+/HER2- early breast cancerNot recorded
Optune / Optune Pax (TTFields)
Device (tumour treating fields)
United KingdomNot recordedNICE: not recommended for glioblastoma (2018 assessment); reassessment pendingNot recorded
Optune / Optune Pax (TTFields)
Device (tumour treating fields)
United StatesNot recordedMedicare covers Optune Gio for newly diagnosed glioblastoma (LCD); Optune Lua and Pax coverage evolvingNot recorded
Osimertinib
Small-molecule kinase inhibitor (EGFR)
ChinaNot recordedNRDL listed since 2019 with major price cutNot recorded
Osimertinib
Small-molecule kinase inhibitor (EGFR)
United KingdomNot recordedNICE: recommended first-line (TA654), adjuvant (TA761), and after chemoradiationNot recorded
Osimertinib
Small-molecule kinase inhibitor (EGFR)
United Statesastrazeneca-us.com/medicines/access-360Medicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Paclitaxel / nab-paclitaxel
Cytotoxic chemotherapy (taxane)
United KingdomNot recordedNHS standard; genericYes
Paclitaxel / nab-paclitaxel
Cytotoxic chemotherapy (taxane)
United StatesNot recordedMedicare Part B; generic paclitaxel and nab-paclitaxel availableYes
Palbociclib
Small-molecule CDK4/6 inhibitor
United KingdomNot recordedNICE: recommended with aromatase inhibitor (TA495) and fulvestrant (TA619)Not recorded
Palbociclib
Small-molecule CDK4/6 inhibitor
United Statespfizeroncologytogether.comMedicare Part D; generic entry expected 2027 in the USNo
Patritumab deruxtecan
ADC
United StatesNot recordedInvestigational; BLA withdrawn May 2025 after HERTHENA-Lung02 OS resultNot recorded
Pembrolizumab
Monoclonal antibody (anti-PD-1)
European UnionNot recordedEMA approved; reimbursed in all member states for core indicationsNot recorded
Pembrolizumab
Monoclonal antibody (anti-PD-1)
United KingdomNot recordedNICE: recommended across many indications (melanoma, NSCLC, TNBC KEYNOTE-522/355, RCC, HNSCC, cervical, oesophageal and others)Not recorded
Pembrolizumab
Monoclonal antibody (anti-PD-1)
United Statesmerckaccessprogram-keytruda.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Piflufolastat F-18 / Pylarify TruVu
PET imaging agent
United StatesNot recordedMedicare pass-through/payment for PSMA PET; broad commercial coverage for staging and biochemical recurrenceNot recorded
Puxitatug samrotecan
ADC
United StatesNot recordedInvestigationalNot recorded
Raludotatug deruxtecan
ADC
United StatesNot recordedInvestigational (REJOICE-Ovarian01)Not recorded
Relacorilant
Small-molecule glucocorticoid receptor antagonist
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Relatlimab + nivolumab
Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)
United KingdomNot recordedNICE: recommended for untreated advanced melanoma, PD-L1 <1% (2024)Not recorded
Relatlimab + nivolumab
Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)
United Statesbmsaccesssupport.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Revumenib
Small-molecule menin inhibitor
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Ribociclib
Small-molecule CDK4/6 inhibitor
United KingdomNot recordedNICE: recommended with aromatase inhibitor (TA496), fulvestrant (TA687), and adjuvant (2025)Not recorded
Ribociclib
Small-molecule CDK4/6 inhibitor
United Statesnovartis.com/us-en/patient-supportMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Sacituzumab govitecan
ADC
European UnionNot recordedEMA approved; national reimbursement variesNot recorded
Sacituzumab govitecan
ADC
United KingdomNot recordedNICE: recommended for pretreated metastatic TNBC (TA819) and HR+/HER2- breast cancer after endocrine therapy and chemotherapyNot recorded
Sacituzumab govitecan
ADC
United Statesgileadadvancingaccess.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Sacituzumab tirumotecan
ADC
ChinaNot recordedNMPA approved 2024; National Reimbursement Drug List inclusion from 2025Not recorded
Sacituzumab tirumotecan
ADC
United StatesNot recordedInvestigational; not yet approvedNot recorded
Satricabtagene autoleucel
CAR-T (Claudin 18.2)
ChinaNot recordedNMPA approved 2025-26; self-payNot recorded
Selpercatinib
Small-molecule kinase inhibitor (RET)
United KingdomNot recordedNICE: recommended for RET-fusion NSCLC and thyroid cancers (TA911, TA742, TA760)Not recorded
Selpercatinib
Small-molecule kinase inhibitor (RET)
United Stateslillycares.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Shield
Blood-based colorectal cancer screening test
United StatesNot recordedMedicare covers Shield every 3 years for average-risk adults 45-85 (2024 NCD); commercial coverage expandingNot recorded
Signatera
Tumour-informed ctDNA MRD test
United StatesNot recordedMedicare covers colorectal (stage II-III and IV), muscle-invasive bladder, breast (neoadjuvant/adjuvant), ovarian, NSCLC and pan-cancer immunotherapy monitoring under MolDX; commercial coverage growingNot recorded
Sonesitatug vedotin
ADC
United StatesNot recordedInvestigational (CLARITY-Gastric01)Not recorded
Sotorasib
Small-molecule inhibitor (KRAS G12C)
United KingdomNot recordedNICE: recommended via Cancer Drugs Fund for KRAS G12C NSCLC after platinum (TA781); later terminated then re-appraisedNot recorded
Sotorasib
Small-molecule inhibitor (KRAS G12C)
United Statesamgensupportplus.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Talazoparib
Small-molecule PARP inhibitor
United KingdomNot recordedNICE: recommended for gBRCA HER2-negative advanced breast cancer (TA952) and with enzalutamide in HRR-mutant mCRPC (2024)Not recorded
Talazoparib
Small-molecule PARP inhibitor
United Statespfizeroncologytogether.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Talimogene laherparepvec
Oncolytic virus (HSV-1)
United KingdomNot recordedNICE: recommended for unresectable melanoma when systemic immunotherapy is unsuitable (TA410)Not recorded
Talimogene laherparepvec
Oncolytic virus (HSV-1)
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Tarlatamab
Bispecific T-cell engager (DLL3×CD3)
United KingdomNot recordedNICE: appraisal for ES-SCLC after platinum in progress (2026)Not recorded
Tarlatamab
Bispecific T-cell engager (DLL3×CD3)
United Statesamgensupportplus.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Tebentafusp
ImmTAC (TCR×CD3 bispecific)
United KingdomNot recordedNICE: recommended for HLA-A*02:01+ metastatic uveal melanoma (TA867)Not recorded
Tebentafusp
ImmTAC (TCR×CD3 bispecific)
United Stateskimmtrak.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Teclistamab
Bispecific T-cell engager (BCMA×CD3)
United KingdomNot recordedNICE: recommended for relapsed/refractory myeloma after ≥3 therapies (TA1006)Not recorded
Teclistamab
Bispecific T-cell engager (BCMA×CD3)
United Statesjanssencarepath.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Telisotuzumab vedotin
ADC
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Tilatamig samrotecan
Bispecific ADC
United StatesNot recordedInvestigationalNot recorded
Tisotumab vedotin
ADC
United KingdomNot recordedNICE: appraisal for recurrent cervical cancer (2025-26)Not recorded
Tisotumab vedotin
ADC
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Trastuzumab
Monoclonal antibody (anti-HER2)
United KingdomNot recordedNICE: standard of care; biosimilars widely usedNot recorded
Trastuzumab
Monoclonal antibody (anti-HER2)
United Statesgenentech-access.comMedicare Part B; five biosimilars available since 2019, roughly 15-35% below reference priceYes
Trastuzumab deruxtecan
ADC
JapanNot recordedNHI listed; approved in HER2+ breast and gastric cancer since 2020Not recorded
Trastuzumab deruxtecan
ADC
United KingdomNot recordedNICE: recommended in HER2+ breast cancer after ≥1 anti-HER2 regimen (TA862) and HER2-low breast cancer (TA1090); HER2-mutant NSCLC via CDFNot recorded
Trastuzumab deruxtecan
ADC
United Statesenhertu4u.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Trastuzumab emtansine
ADC
United KingdomNot recordedNICE: recommended for residual invasive disease after neoadjuvant therapy (TA632) and HER2+ metastatic disease (TA458)Not recorded
Trastuzumab emtansine
ADC
United Statesgenentech-access.comMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Tucatinib
Small-molecule kinase inhibitor (HER2)
United KingdomNot recordedNICE: recommended with trastuzumab and capecitabine for HER2+ breast cancer after ≥2 anti-HER2 regimens (TA786)Not recorded
Tucatinib
Small-molecule kinase inhibitor (HER2)
United Statespfizeroncologytogether.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Venetoclax
Small-molecule BCL-2 inhibitor
United KingdomNot recordedNICE: recommended in CLL (TA487, TA561, TA663) and AML with azacitidine (TA765)Not recorded
Venetoclax
Small-molecule BCL-2 inhibitor
United Statesvenclexta.com/supportMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Vepdegestrant
PROTAC oestrogen receptor degrader
United Statespfizeroncologytogether.comMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Vorasidenib
Small-molecule IDH1/2 inhibitor
United KingdomNot recordedNICE: recommended for grade 2 IDH-mutant glioma after surgery (2025)Not recorded
Vorasidenib
Small-molecule IDH1/2 inhibitor
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Vusolimogene oderparepvec
Oncolytic virus (HSV-1)
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Zanidatamab
Biparatopic bispecific antibody (HER2)
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Zenocutuzumab
Bispecific antibody (HER2×HER3)
United StatesNot recordedMedicare Part B (physician-administered); commercial plans per formularyNot recorded
Zidesamtinib
Small-molecule kinase inhibitor (ROS1)
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded
Zilovertamab vedotin
ADC
United StatesNot recordedInvestigationalNot recorded
Zongertinib
Small-molecule kinase inhibitor (HER2)
United StatesNot recordedMedicare Part D (oral); commercial plans per formulary, often with prior authorisationNot recorded

National schemes and charities: all countries

Figures only where the linked page states them.
Public schemeUnited States
Medicare Part D yearly out-of-pocket cap

Who: Anyone with Medicare drug coverage (a Part D plan or a Medicare Advantage plan with drug cover) taking oral cancer drugs and other pharmacy-dispensed medicines.

What: Since 2025 there is a yearly limit on what you pay out of pocket for covered Part D drugs; once you reach it you pay nothing more for covered drugs that year. Medicare publishes the current year's amount. You can also spread payments over the year through the Medicare Prescription Payment Plan.

  1. Check that the drug is on your plan's formulary; infused drugs given in a clinic are usually Part B, not Part D, and the cap does not apply to them.
  2. Ask your plan about the Medicare Prescription Payment Plan if a large bill lands early in the year.
  3. Compare plans each autumn during open enrolment; formularies and tiers change.

Source: Medicare.gov: costs for Medicare drug coverage · checked 2026-09-09

Public schemeUnited States
Extra Help (Part D low-income subsidy)

Who: People with Medicare who have limited income and resources.

What: Pays the Part D premium and deductible and reduces copayments for covered drugs; there is no late-enrolment penalty while you receive it.

  1. Apply through Social Security online or by phone; people on Medicaid, Supplemental Security Income or a Medicare Savings Program qualify automatically.
  2. Once approved, tell your Part D plan so copayments are adjusted.

Source: Medicare.gov: help with drug costs · checked 2026-09-09

Public schemeUnited States
340B Drug Pricing Program

Who: Patients treated at safety-net hospitals, community health centres and other covered entities.

What: Lets those providers buy outpatient drugs at discounted prices; many use the savings to fund free or reduced-cost medicines and services for uninsured and under-insured patients. The discount does not flow to you automatically, so ask.

  1. Ask the hospital's financial counsellor or pharmacy whether it is a 340B covered entity and what patient discount or charity programme it runs.
  2. Bring proof of income and insurance status.

Source: HRSA: Office of Pharmacy Affairs (340B) · checked 2026-09-09

ManufacturerUnited States
Manufacturer patient assistance and copay programmes

Who: Uninsured or under-insured patients (free-drug programmes) and commercially insured patients (copay cards). Copay cards cannot be used with Medicare or Medicaid.

What: Free or reduced-cost supply of a branded drug, or a card that covers the copay. Each product has its own programme; the manufacturer links in the table above go straight to them.

  1. Find the programme for your drug in the table above, or search NeedyMeds by drug name.
  2. Your clinic's financial navigator or the infusion pharmacy usually enrols you; income documents and a prescription are needed.
  3. Re-enrol each year and whenever your insurance changes.

Source: NeedyMeds programme directory · checked 2026-09-09

CharityUnited States
Patient Advocate Foundation Co-Pay Relief

Who: Insured patients with a qualifying diagnosis and household income under the programme's limit; funds open and close by disease.

What: Direct payment of copays, coinsurance and deductibles for treatment of the covered diagnosis.

  1. Check whether the fund for your cancer is open on the Co-Pay Relief site.
  2. Apply online or by phone with your diagnosis, insurance and income details; your provider can bill the fund directly.

Source: PAF Co-Pay Relief · checked 2026-09-09

CharityUnited States
CancerCare financial assistance

Who: People in active cancer treatment who meet income guidelines.

What: Limited grants for treatment-related costs such as transport, home care and child care, plus copay assistance funds for some diagnoses, and free counselling from oncology social workers.

  1. Call or apply online; an oncology social worker screens eligibility and can point to other funds.

Source: CancerCare: financial assistance · checked 2026-09-09

CharityUnited States
HealthWell Foundation

Who: Insured patients whose fund for a specific disease is open and whose income is under the fund's limit.

What: Grants toward copays, premiums and deductibles for the covered disease.

  1. Search the open funds list for your cancer type.
  2. Apply online; grants are paid to the pharmacy or provider.

Source: HealthWell Foundation · checked 2026-09-09

CharityUnited States
Leukemia & Lymphoma Society Co-Pay Assistance Program

Who: Insured patients with a blood cancer covered by an open fund.

What: Help with insurance premiums and copays for treatment of the covered blood cancer.

  1. Check the open diagnoses on the LLS site and apply online or through an LLS information specialist.

Source: LLS Co-Pay Assistance Program · checked 2026-09-09

CharityUnited States
American Cancer Society Road To Recovery

Who: Patients who need a ride to treatment and cannot drive themselves.

What: Free rides to and from treatment from trained volunteer drivers, where the programme operates.

  1. Call the ACS helpline or request a ride online a few days in advance.

Source: ACS Road To Recovery · checked 2026-09-09

CharityUnited States
American Cancer Society Hope Lodge

Who: Patients and a caregiver travelling away from home for treatment.

What: Free lodging near treatment centres in the cities where a Hope Lodge operates.

  1. Ask your treatment centre's social worker to refer you, or contact the Lodge directly; availability varies.

Source: ACS Hope Lodge · checked 2026-09-09

Public schemeUnited Kingdom
Free NHS prescriptions with a medical exemption certificate

Who: Anyone in England being treated for cancer, its effects, or the effects of treatment. Prescriptions are already free in Scotland, Wales and Northern Ireland.

What: All NHS prescriptions free of charge for five years, renewable, not only the cancer drugs.

  1. Ask your GP surgery or hospital for form FP92A; a clinician signs it.
  2. The certificate arrives from the NHS Business Services Authority; tick the exemption box on the prescription form and show the certificate if asked.

Source: NHSBSA: medical exemption certificates · checked 2026-09-09

CharityUnited Kingdom
Macmillan Grants

Who: People living with cancer on a low income and with limited savings.

What: A one-off payment towards costs such as heating, travel to hospital, clothing or household items.

  1. A health or social care professional (for example a Macmillan nurse or hospital social worker) applies with you.
  2. Macmillan's support line can check eligibility and connect you with a professional to apply.

Source: Macmillan Grants · checked 2026-09-09

Public schemeUnited Kingdom
Personal Independence Payment (PIP)

Who: People aged 16 to State Pension age in England and Wales whose illness or treatment affects daily living or mobility; Scotland has Adult Disability Payment.

What: A regular, non-means-tested payment. People who are terminally ill can claim under special rules with a faster decision and no assessment.

  1. Start the claim by phone or online on GOV.UK.
  2. Ask your clinical team for the SR1 form if you may qualify under the special rules for end of life.
  3. Macmillan and Citizens Advice can help fill in the forms.

Source: GOV.UK: Personal Independence Payment · checked 2026-09-09

Public schemeUnited Kingdom
Attendance Allowance

Who: People over State Pension age who need help with personal care or supervision because of illness.

What: A regular, non-means-tested payment at one of two rates; special rules apply for terminal illness.

  1. Claim by post using the form on GOV.UK or by phone; the special-rules route uses the SR1 form from your clinician.

Source: GOV.UK: Attendance Allowance · checked 2026-09-09

Public schemeUnited Kingdom
Cancer Drugs Fund (England)

Who: NHS patients in England whose oncologist recommends a drug that NICE has placed in the Fund while more evidence is collected.

What: Interim NHS funding for promising drugs that are not yet in routine commissioning; your clinician applies, not you. The 'What the NHS offers' page lists which products are in the Fund.

  1. Ask your oncologist whether the treatment is in the CDF and whether you meet the treatment criteria.
  2. The hospital submits the application; the drug is then supplied free on the NHS.

Source: NHS England: Cancer Drugs Fund · checked 2026-09-09

CharityUnited Kingdom
Maggie's centres

Who: Anyone with cancer, and their family and friends, near a Maggie's centre.

What: Free practical, emotional and financial support, including benefits advice from trained advisers, without an appointment.

  1. Walk in to a centre, most of which sit next to NHS cancer hospitals, or contact one online.

Source: Maggie's · checked 2026-09-09

Legal rightEuropean Union
Cross-border healthcare (Directive 2011/24/EU)

Who: People insured in an EU or EEA country who want treatment or a consultation in another member state.

What: Reimbursement by your home insurer up to what the same care would have cost at home; prior authorisation may be required for hospital stays and costly treatments. National schemes for cancer drugs and copayments differ by country, so ask your national contact point.

  1. Find your national contact point through the Your Europe portal.
  2. Ask whether prior authorisation is needed before travelling.
  3. Keep invoices and reports for reimbursement.

Source: Directive 2011/24/EU · checked 2026-09-09

Public schemeAustralia
PBS co-payment and Safety Net

Who: Anyone with a Medicare card filling PBS-listed prescriptions, including most oral cancer drugs; concession card holders pay a lower co-payment.

What: Subsidised medicines with a fixed co-payment per script. Once a family's spending reaches the yearly Safety Net threshold, scripts for the rest of the year are cheaper or free for concession holders. Services Australia publishes the current thresholds.

  1. Ask one pharmacy to keep a Prescription Record Form, or ask each pharmacy to record your scripts, so spending is tracked for the Safety Net.
  2. Apply for a Safety Net card when the threshold is reached.

Source: Services Australia: PBS Safety Net thresholds · checked 2026-09-09

Public schemeAustralia
Medicare Safety Nets

Who: Anyone with high out-of-hospital costs, for example specialist consultations, scans and radiotherapy given as an outpatient.

What: Once your gap payments in a calendar year pass a threshold, Medicare pays a higher share of further out-of-hospital costs for the rest of the year.

  1. Register as a family or couple with Services Australia so costs are pooled.
  2. Services Australia tracks the total from claims automatically.

Source: Services Australia: Medicare Safety Nets · checked 2026-09-09

CharityAustralia
Cancer Council practical and financial assistance

Who: People affected by cancer in any state or territory.

What: Financial counselling, legal and workplace advice through the Pro Bono Program, transport and accommodation help for people travelling to treatment, and referral to state patient travel assistance schemes.

  1. Call 13 11 20 or contact your state Cancer Council; a nurse or counsellor screens and refers you.

Source: Cancer Council: practical and financial assistance · checked 2026-09-09

Public schemeJapan
High-Cost Medical Expense Benefit (kougaku ryouyouhi seido)

Who: Everyone enrolled in Japanese public health insurance, which is compulsory for residents.

What: A monthly ceiling on what you pay for insured medical care, set by age and income band; the insurer reimburses anything above it, and the ceiling falls further after several high-cost months in a year.

  1. Ask your insurer for a Certificate of Eligibility for Ceiling-Amount Application (gendogaku tekiyou ninteishou) before treatment so the hospital bills you only up to the ceiling.
  2. Without the certificate, pay and then claim reimbursement from the insurer.

Source: Ministry of Health, Labour and Welfare (Japanese) · checked 2026-09-09

Public schemeChina
National Reimbursement Drug List (NRDL)

Who: People covered by basic medical insurance, which covers most residents.

What: Cancer drugs added to the list after national price negotiation are reimbursed at a share set by the provincial scheme; drugs not on the list are largely self-pay. The list is updated each year, and many new targeted drugs and immunotherapies have been added through negotiation.

  1. Ask the hospital pharmacy whether your drug is on the current NRDL and what the local reimbursement share is.
  2. Some hospitals and provinces also run supplementary insurance (huiminbao) and charity supply programmes for drugs not yet listed; ask the social worker or the manufacturer.

Source: National Healthcare Security Administration · checked 2026-09-09

Public schemeCanada
Provincial and territorial cancer drug programmes

Who: Residents with a provincial health card. Coverage rules differ by province: hospital-administered drugs are covered everywhere, while take-home oral cancer drugs are covered fully in some provinces and through public drug plans with deductibles in others.

What: Public funding of cancer drugs recommended by Canada's Drug Agency and negotiated by the pan-Canadian Pharmaceutical Alliance, then listed by each province.

  1. Ask your cancer centre's drug access navigator which programme covers your drug where you live.
  2. If a take-home drug is not covered, ask about the provincial drug plan, private insurance and the manufacturer's patient support programme.

Source: pan-Canadian Pharmaceutical Alliance · checked 2026-09-09

CharityCanada
Canadian Cancer Society financial help

Who: People affected by cancer anywhere in Canada.

What: Guidance on income supports, tax credits and drug coverage, plus travel and lodging programmes near treatment centres.

  1. Call the Cancer Information Helpline or use the community services locator on the site.

Source: Canadian Cancer Society: financial help · checked 2026-09-09

Patient organisations with financial and practical help

Alex's Lemonade Stand Foundation (ALSF)

A childhood-cancer charity started by a four-year-old patient's lemonade stand that now funds hundreds of grants and runs an open-science data lab for paediatric cancer genomics.

alexslemonade.org
American Cancer Society (ACS)

The American Cancer Society is the largest US cancer charity: the source of the widely quoted annual US cancer statistics, screening recommendations that differ from the USPSTF in places, and plain-language patient guides for every cancer.

cancer.org
Colorectal Cancer Alliance

The Colorectal Cancer Alliance is the largest US colorectal cancer patient organisation, focused on screening uptake from age 45, young-onset disease and connecting patients with biomarker-matched trials.

colorectalcancer.org
Leukemia & Lymphoma Society (LLS)

The Leukemia & Lymphoma Society is the main US blood-cancer charity, unusual for running its own precision-medicine trials (Beat AML, PedAL) and investing directly in biotech, alongside co-pay assistance and one-to-one information specialists.

lls.org
LUNGevity Foundation (and GO2 for Lung Cancer)

LUNGevity is the largest US lung cancer charity, focused on making sure every patient gets comprehensive biomarker testing and access to targeted therapy and trials, with a screening-advocacy partner in GO2.

lungevity.org
Lymphoma Research Foundation (LRF)

The Lymphoma Research Foundation is the largest US lymphoma-specific charity, with plain-language guides for over 20 lymphoma subtypes and a research programme focused on mantle cell and adolescent/young adult lymphoma.

lymphoma.org
Melanoma Research Alliance (MRA)

A melanoma research funder created in 2007 by the Milken family that backed early immunotherapy and targeted-therapy work and now focuses on rare melanoma subtypes and resistance.

curemelanoma.org
Multiple Myeloma Research Foundation (MMRF)

A myeloma foundation that built the most important open genomic dataset in the disease (CoMMpass) and funded much of the science behind today's therapies; also a patient support and navigation resource.

themmrf.org
National Brain Tumor Society (NBTS)

The National Brain Tumor Society is the largest US brain tumour nonprofit, notable for helping create GBM AGILE, the adaptive platform trial that tests many glioblastoma drugs at once, and for its advocacy on FDA endpoints for brain tumours.

braintumor.org
Ovarian Cancer Research Alliance (OCRA)

The Ovarian Cancer Research Alliance is the largest US ovarian cancer organisation, born from the merger of research and patient-support charities; it funds research and campaigns for universal genetic testing and prevention by salpingectomy given that screening does not work.

ocrahope.org
Pancreatic Cancer Action Network (PanCAN)

PanCAN is the leading pancreatic cancer patient organisation; it pioneered free tumour molecular profiling for patients (Know Your Tumor) and runs an adaptive platform trial for a disease with few options.

pancan.org
Prostate Cancer Foundation (PCF)

Michael Milken's prostate cancer foundation, which funded the science behind abiraterone, enzalutamide and PSMA therapy and runs a precision-oncology network in US veterans' hospitals.

pcf.org
St. Baldrick's Foundation

A head-shaving fundraiser that became the largest charitable funder of children's cancer research in the US, underwriting much of the cooperative-group trial infrastructure that treats most American children with cancer.

stbaldricks.org
Susan G. Komen

Susan G. Komen is the best-known breast cancer charity, a major funder of research and a large provider of patient navigation and financial assistance, with a patient-driven research registry that shares data for metastatic breast cancer research.

komen.org

Most are US-based and disease-specific; many run copay funds, travel grants or navigation lines. In the UK, Macmillan and Maggie's are the first call; in Australia, Cancer Council.

Financial toxicity is a treatment side effect. Ask the team for a financial navigator or oncology social worker at the first visit, not when the bills arrive; most centres have one. See the bottlenecks section for why cancer care costs what it does, paying for care in the US and what the NHS offers.